Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome.
Emerg Infect Dis
; 26(6): 1102-1112, 2020 Jun.
Article
in English
| MEDLINE | ID: covidwho-17702
ABSTRACT
Available animal and cell line models have suggested that specific therapeutics might be effective in treating Middle East respiratory syndrome (MERS). We conducted a systematic review of evidence for treatment with pharmacologic and supportive therapies. We developed a protocol and searched 5 databases for studies describing treatment of MERS and deaths in MERS patients. Risk of bias (RoB) was assessed by using ROBINS-I tool. We retrieved 3,660 unique citations; 20 observational studies met eligibility, and we studied 13 therapies. Most studies were at serious or critical RoB; no studies were at low RoB. One study, at moderate RoB, showed reduced mortality rates in severe MERS patients with extracorporeal membrane oxygenation; no other studies showed a significant lifesaving benefit to any treatment. The existing literature on treatments for MERS is observational and at moderate to critical RoB. Clinical trials are needed to guide treatment decisions.
Keywords
CoV; MERS; Middle East respiratory syndrome; acute respiratory distress syndrome; antivirals; convalescent plasma; coronavirus; coronavirus infections; corticosteroids; interferon; intravenous immunoglobulin; respiratory infections; ribavirin; severe acute respiratory syndrome; supportive care; systematic review; viruses; zoonoses
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Coronavirus Infections
/
Middle East Respiratory Syndrome Coronavirus
Type of study:
Observational study
/
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Limits:
Humans
Language:
English
Journal:
Emerg Infect Dis
Journal subject:
Communicable Diseases
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS